Health Update: weight The downsizing market is no longer confined to the big metros. Increasing availability of affordable GLP-1 options and digital healthcare services has led to a huge increase in demand for medical weight management in tier-2 and tier-3 cities. According to the report, demand for physician-supervised treatment for weight, diabetes, and metabolic issues among women appears to be increasing. According to Pharmaceuticals data, the GLP-1 agonist market in India reached an estimated Rs 1,906 crore in May 2026, up from an estimated Rs 565 crore in the previous year. This rapid market growth was mainly driven by the entry of lower cost generic alternatives to semaglutide.(Photo courtesy – istock)
Prime Minister Narendra Modi advised to eat amla! Consuming foods rich in powerful ingredients will keep you healthy forever
Why is the demand for weight management increasing?
After the Indian patent of semaglutide expired in March 2026, several domestic companies launched generic versions. This has significantly reduced the cost of treatment. Some generic alternatives cost much less than the original band. This is likely to increase the reach of GLP-1-based treatments in Tier-2 and Tier-3 cities as well. In women, conditions such as PCOS (polycystic ovary syndrome), insulin resistance and obesity may increase the need for weight management treatments.
Precautions to be taken while taking the medicine:
GLP-1 medicines are not suitable for everyone. These medicines should be used only under the advice and supervision of a doctor. Experts also advise caution regarding the use and misuse of cosmetics. Apart from Mumbai in Maharashtra, this market can be instrumental in expanding the availability of healthcare services and specialist doctors in cities like Pune, Nagpur, Nashik, Sambhajinagar and Kolhapur.
Diabetic Retinopathy: Don't think your eyes are healthy just because they look! Recognize the risk of retinal disease
Key statistics of GLP-1 market
- Market in May 2026: 1,906 crore
- 565 crore approximately a year ago
- Main drugs: Semaglutide, Tirizeptide
- Semaglutide Patent: Expires in March 2026
- A major reason for market expansion is low-cost generic alternatives
- Increasing reach: Metro cities as well as Tier-2 and Tier-3 cities
- Key uses: Type 2 diabetes and medical weight management